Pharmaceuticals

For the fourth year, McLaren's KSP earns a rare 'Pioneer' award from URAC, not just for its performance, but for helping shape the future of patient care.

An upcoming FDA meeting on peptide compounding is more than a regulatory footnote. It's a battleground for the future of personalized and preventive care.

At AIDS 2026, ViiV Healthcare unveils data challenging treatment norms, proving long-acting injectable efficacy, and paving the way for quarterly PrEP.

Berlin-based OMEICOS gets a major FDA boost, advancing its novel PMD drug OMT-28 directly to a pivotal Phase 3 trial. A deep dive into the science.

Arcturus Therapeutics heads to the Canaccord Growth Conference to spotlight its advanced mRNA platform, shifting focus from COVID vaccines to rare diseases.

New research reveals how IntraBio's AQNEURSA recalibrates cellular function, a novel mechanism that could revolutionize treatment for a wide range of diseases.

A Rwandan-owned company reports promising results for a long-acting TB drug. It could transform treatment, but it also signals a shift in global health innovation.

A new study validates Actinogen's cortisol-inhibiting drug for depression, creating a strategic tailwind for its primary Alzheimer's program due in November.

Kamada's new plasma supply agreement is more than just revenue; it's a bold validation of its vertical integration strategy in a competitive global market.

With a new CEO famed for a $2.4B exit and a reverse merger in play, Mentari Therapeutics isn't just developing drugs; it's building a powerhouse.

Lundbeck completes enrollment for a pivotal trial testing a novel drug for severe childhood epilepsies. But what are the real stakes for patients and investors?

A struggling medtech firm and an AI drug developer merge. It's not just a deal; it's a new blueprint for innovation, funded by high-risk capital.

Kibow Biotech's AANP award for its kidney health probiotics isn't just a win for the company; it's a major nod to the growing role of the gut-kidney axis.

A new study reveals the thriving, high-risk market for compounded weight-loss drugs. Even after FDA shortages ended, some clinics use unregulated suppliers.

VST Capital’s Atlas Healthcare Fund is posting staggering returns by ignoring financial models and reading lab reports. Is this the future of investing?

With $9M in new funding, Trellis Bioscience advances a novel antibody that shatters bacterial defenses, offering hope for devastating joint infections.

With its MASH drug Rezdiffra a certified blockbuster, Madrigal's upcoming Q2 report will reveal if its meteoric rise can be sustained against new rivals.

Fresh off a massive Moderna settlement, Arbutus Biopharma expands its patent war against Pfizer and plans a $230M shareholder return, a bold strategic move.

Curative Biotechnology secures a key U.S. patent for a metformin eye-drop, a novel approach that could transform treatment for macular degeneration.

With mortality rates over 50%, cardiogenic shock has long eluded targeted treatment. Now, a novel antibody from 4TEEN4 gets an FDA fast track.